No­vo Nordisk ax­es 2 more obe­si­ty drugs as lead­ing drugs 'raise the bar'; Div­ing deep­er in­to R&D, CSL adds sup­port for biotech in­cu­ba­tor

No­vo Nordisk is once again whit­tling away at its pipeline of obe­si­ty drugs.

In it lat­est quar­ter­ly up­date the phar­ma com­pa­ny not­ed:

In June 2020 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.